Fig. 8

The prediction of immunotherapeutic and chemotherapeutic responses. A) SubMap analysis revealed that the low-risk group was more sensitive to PD-1 inhibitor (Bonferroni-corrected P = 0.008); B) The predicted IC50 for chemotherapeutic drugs in the low- and high-risk group. The low-risk group was related to a lower IC50 in docetaxel, gefitinib and vinblastine, while the high-risk group was related to a lower IC50 in doxorubicin, mitomycin C and paclitaxel (P < 0.05 by Wilcoxon test)